Cardiovascular Research

Erectile dysfunction in the cardiac patient.

Authors: Robert A Kloner

Affiliations: + Expand

Abstract

Erectile dysfunction (ED) often is caused by endothelial dysfunction and may be a sign that a patient has vascular disease elsewhere in the body. Risk factors for coronary artery disease such as lipid abnormalities, smoking, diabetes, and hypertension also are risk factors for ED. Oral therapy for ED, such as sildenafil, inhibits phosphodiesterase-5 (PDE-5) and the breakdown of cyclic guanosine monophosphate. PDE-5 inhibitors have been shown to be safe and effective for the therapy for ED, but remain contraindicated in patients receiving organic nitrates. These agents are mild vasodilators and are being investigated for their treatment potential for patients with pulmonary hypertension, heart failure, and endothelial dysfunction.

---

Chemical List

Antihypertensive Agents|||Phosphodiesterase Inhibitors|||Piperazines|||Purines|||Sulfones|||Sildenafil Citrate|||Phosphoric Diester Hydrolases|||3',5'-Cyclic-GMP Phosphodiesterases|||Cyclic Nucleotide Phosphodiesterases, Type 5|||PDE5A protein, human

---

Reference List

Circulation. 2002 May 21;105(20):2398-403|||Lancet. 1985 Jan 26;1(8422):181-4|||Am J Cardiol. 2002 Jun 1;89(11):1331-4|||J Am Coll Cardiol. 1999 Jan;33(1):273-82|||JAMA. 1996 May 8;275(18):1405-9|||Am J Cardiol. 1999 Mar 4;83(5A):35C-44C|||J Am Coll Cardiol. 2000 Sep;36(3):845-51|||J Clin Invest. 1990 Jul;86(1):228-34|||N Engl J Med. 2000 Jun 1;342(22):1622-6|||Urology. 2001 Sep;58(3):441-5|||Circulation. 2001 Sep 11;104(11):1218-22|||Am J Hypertens. 2001 Jan;14(1):27-31|||Am J Cardiol. 2000 Jul 15;86(2):175-81|||Am J Epidemiol. 1994 Nov 15;140(10):930-7|||J Hypertens. 2000 Dec;18(12):1865-9|||N Engl J Med. 1995 Feb 23;332(8):481-7|||N Engl J Med. 1990 Jul 5;323(1):22-7|||J Urol. 2003 Aug;170(2 Pt 2):S46-50; discussion S50|||JAMA. 2002 Feb 13;287(6):719-25|||N Engl J Med. 1998 May 14;338(20):1397-404|||Am J Cardiol. 1999 Feb 15;83(4):576-82, A7|||Curr Atheroscler Rep. 2002 Sep;4(5):397-401|||Circulation. 1996 Aug 1;94(3):258-65|||Am J Cardiol. 2002 Sep 15;90(6):677-80|||Am J Physiol. 1996 Apr;270(4 Pt 2):H1435-40|||BMJ. 2001 Mar 17;322(7287):651-2|||Am J Cardiol. 1999 Mar 4;83(5A):21C-28C|||Diabetes Care. 2002 Aug;25(8):1336-9|||J Urol. 1996 May;155(5):1795-800|||Circulation. 2002 Aug 27;106(9):1097-103|||Prev Med. 2000 Apr;30(4):328-38|||Diabetes Care. 1996 Feb;19(2):135-41|||Urology. 2002 Sep;60(2 Suppl 2):67-90|||J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12|||Am J Cardiol. 1999 Mar 4;83(5A):29C-34C|||Am J Hypertens. 2001 Jan;14(1):70-3|||J Urol. 1994 Jan;151(1):54-61|||Lancet. 2002 Sep 21;360(9337):895-900